Bayer has had a rocky period, with its
stocks seeing
significant fluctuations. Facing multiple legal disputes, the pharmaceutical giant experienced its worst day ever, with shares falling to the lowest level in over a decade. Several setbacks like the $1.5bn Roundup verdict, drug failures and dividend cuts to address mounting debt have pulled down the stock. In more recent news, Bayer-backed Metagenomi's shares dropped 32% on its Nasdaq debut, further causing concern among investors. Faced with budgetary limits,
management restructuring is underway and further managerial job cuts in the company’s pharmaceutical unit are expected. The company’s
first-quarter adjusted profit ended up falling less than projected, providing some respite. However, the scaling down of dividends due to mounting Roundup woes and ongoing legal challenges has added to the market volatility of Bayer stocks. In notable advancements, the company’s menopause drug has shown positive results in late-stage trials. Despite the challenges, Goldman Sachs maintains a €31 target on Bayer shares, keeping it at Neutral.
BAYER Stocks News Analytics from Fri, 15 Sep 2023 07:00:00 GMT to Thu, 01 Aug 2024 07:00:00 GMT -
Rating -6
- Innovation -4
- Information 2
- Rumor -2
